Viral Inactivation Market - Global Forecast to 2021

The global viral inactivation market is projected to reach USD 573.0 million by 2021 from USD 320.5 million in 2016, at a CAGR of 12.3% from 2016 to 2020. The major drivers for the market include increase in pharmaceutical and biological industries and increasing number of new drug launches. Over the years, the number of drug approvals in North American countries has increased from 2006 to 2015. In 2015, the FDA’s Center for Drug Evaluation and Research (CDER) approved 45 novel drugs, approved as new molecular entities (NMEs) under New Drug Applications (NDAs) or as new therapeutic biologics under Biologics License Applications (BLAs) as compared to 22 novel drugs approved in 2006. The increasing number of drug approvals will boost the viral inactivation market.

According to OECD estimates, in 2011, the total number of biotechnology companies in the U.S. was 7,970, followed by Spain (3,025 biotechnology companies), and France (1,481 biotechnology companies). Owing to the rise in the number of biotechnology companies, biopharmaceutical production has increased globally. Viral inactivation is carried out at all levels of pharmaceutical and biopharmaceutical manufacturing process to minimize the risk of product contamination. Growth in pharmaceutical and biotechnology industries will drive the growth of the viral inactivation market.

This report segments the global viral inactivation market is segmented based on method, product, application, end user, and geography. The method segments included in the report are solvent detergent method, pasteurization, and other methods. Other viral inactivation method includes low pH, microwave heating, irradiation, and high-energy light.

The product segments included in the report are kits and reagents, services, and viral inactivation systems and accessories.

The application segments included in the report are blood & blood products, cellular & gene therapy products, stem cell products, tissue & tissue products, and vaccines and therapeutics.

Based on end user this market is categorized into pharmaceutical and biotechnology companies, contract research organizations, academic research institutes, and other end users.

The geographic segments included in this report are Asia, Europe, North America and the Rest of the World (RoW). North America is further divided into Canada and the U.S. Asia is further divided in to China, Japan, India, and Rest of Asia.

The report provides qualitative insights on key market shares, growth rates, and market drivers for all important subsegments. It maps market sizes and growth rates of each subsegment and identifies segments poised to see rapid growth. The report also includes company profiles of market leaders. These company profiles include the financial performances, product portfolios, and developments of each company. The report also provides a competitive landscape of the viral inactivation market. The competitive landscape covers the growth strategies adopted by industry players over the last three years. It also includes analyses of industry developments like mergers and acquisitions, agreements and partnerships, and new product launches.

Reasons to Buy the Report:

The report will enable both established firms and new entrants to gauge the pulse of the market and help them make important strategic growth decisions.

The report provides insights on the following:
‧ Product Development/Innovation: Product portfolios of top players in the viral inactivation market. Detailed insights on upcoming technologies, research and development activities, and new product launches in the viral inactivation market
‧ Competitive Assessment: In-depth assessment of market shares, strategies, geographic and business segments, and product portfolios of leading players in the viral inactivation market
‧ Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the market for various viral inactivation products across geographies
Market Diversification: Exhaustive information about new products and services, recent developments, and investments in the viral inactivation market

TABLE OF CONTENTS

1 INTRODUCTION 13
1.1 OBJECTIVES OF THE STUDY 13
1.2 MARKET DEFINITION 13
1.2.1 MARKETS COVERED 14
1.2.2 YEARS CONSIDERED FOR THE STUDY 14
1.3 CURRENCY 15
1.4 LIMITATIONS 15
1.5 STAKEHOLDERS 15
2 RESEARCH METHODOLOGY 16
2.1 MARKET SIZE ESTIMATION 17
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION 20
2.3 MARKET SHARE ESTIMATION 21
2.3.1 KEY DATA FROM SECONDARY SOURCES 21
2.3.2 KEY DATA FROM PRIMARY SOURCES 22
2.3.3 ASSUMPTIONS 22
3 EXECUTIVE SUMMARY 23
4 PREMIUM INSIGHTS 28
4.1 GLOBAL VIRAL INACTIVATION MARKET OVERVIEW 28
4.2 LIFE CYCLE ANALYSIS, BY REGION 30
5 MARKET OVERVIEW 32
5.1 INTRODUCTION 33
5.1.1 MARKET SEGMENTATION 33
5.2 MARKET DYNAMICS 34
5.2.1 DRIVERS 35
5.2.1.1 Rapid growth in pharmaceutical and biotechnology industries 35
5.2.1.2 Increasing number of new drug launches 35
5.2.1.3 Strong R&D investments in the life sciences industry 36
5.2.1.4 Increasing government support for pharmaceutical and biotechnology industries 36
5.2.1.5 High incidence and large economic burden of chronic diseases 37
5.2.2 RESTRAINT 38
5.2.2.1 High degree of consolidation to act as a major barrier for new entrants 38
5.2.3 OPPORTUNITIES 38
5.2.3.1 Increasing pharmaceutical outsourcing 38
5.2.3.2 Developing countries present significant growth opportunities for the viral inactivation market 39
5.2.4 CHALLENGE 39
5.2.4.1 Stringent regulatory frameworks and time-consuming approval processes for viral inactivation products 39
6 VIRAL INACTIVATION MARKET, BY METHOD 41
6.1 INTRODUCTION 42
6.2 SOLVENT DETERGENT METHOD 43
6.3 PASTEURIZATION 44
6.4 OTHER METHODS 45
7 VIRAL INACTIVATION MARKET, BY PRODUCT 47
7.1 INTRODUCTION 48
7.2 KITS AND REAGENTS 49
7.3 SERVICES 50
7.4 VIRAL INACTIVATION SYSTEMS AND ACCESSORIES 52
8 VIRAL INACTIVATION MARKET, BY APPLICATION 54
8.1 INTRODUCTION 55
8.2 VACCINES AND THERAPEUTICS 56
8.3 BLOOD AND BLOOD PRODUCTS 58
8.4 CELLULAR AND GENE THERAPY PRODUCTS 59
8.5 TISSUES AND TISSUE PRODUCTS 61
8.6 STEM CELL PRODUCTS 62
9 VIRAL INACTIVATION MARKET, BY END USER 64
9.1 INTRODUCTION 65
9.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 67
9.3 CONTRACT RESEARCH ORGANIZATIONS 68
9.4 ACADEMIC RESEARCH INSTITUTES 70
9.5 OTHER END USERS 71
10 VIRAL INACTIVATION MARKET, BY GEOGRAPHY 73
10.1 INTRODUCTION 74
10.2 NORTH AMERICA 76
10.2.1 U.S. 83
10.2.2 CANADA 85
10.3 EUROPE 87
10.4 ASIA 92
10.4.1 CHINA 99
10.4.2 JAPAN 101
10.4.3 INDIA 103
10.4.4 REST OF ASIA 105
10.5 REST OF THE WORLD 107
11 COMPETITIVE LANDSCAPE 111
11.1 OVERVIEW 111
11.2 STRATEGIC OVERVIEW 111
11.3 LEADING PLAYERS IN THE VIRAL INACTIVATION MARKET 112
11.4 COMPETITIVE SITUATION AND TRENDS 114
11.4.1 EXPANSIONS 115
11.4.2 ACQUISITIONS 116
11.4.3 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS 117
11.4.4 SERVICES LAUNCHES 118
12 COMPANY PROFILES 119
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
12.1 INTRODUCTION 119
12.2 DANAHER CORPORATION 120
12.3 MERCK KGAA 123
12.4 PARKER HANNIFIN CORPORATION 126
12.5 SARTORIUS AG 129
12.6 SGS SA 132
12.7 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 135
12.8 CLEAN CELLS INC. 138
12.9 RAD SOURCE TECHNOLOGIES, INC. 139
12.10 TEXCELL, INC. 140
12.11 VIRAL INACTIVATED PLASMA SYSTEMS SA 141
12.12 WUXI PHARMATECH (CAYMAN) INC. 142

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.
13 APPENDIX 145
13.1 INSIGHTS OF INDUSTRY EXPERTS 145
13.2 DISCUSSION GUIDE 146
13.3 OTHER DEVELOPMENTS 148
13.4 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 150
13.5 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 152
13.6 AVAILABLE CUSTOMIZATIONS 153
13.7 RELATED REPORTS 154